跳至主要内容
临床试验/EUCTR2008-000424-86-NL
EUCTR2008-000424-86-NL进行中(未招募)不适用

Development and introduction of a pediatric liquid formulation of 6-mercaptopurine for treatment of leukemia - 6MP formulation

Erasmus MC0 个研究点开始时间: 2008年8月5日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Erasmus MC

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Histologically or cytologically confirmed diagnosis of ALL
  • -Inclusion in DCOG ALL-10 or Interfant-06 protocol
  • -Recovered from acute side-effects of previous treatment blocks
  • -Lansky play score > 60; or Karnofsky performance status > 60
  • -Normal liver function defined as less than or equal to NCI-CTG grade 1 (max 2.5 x ULN for transaminases and bilirubin)
  • -Able to comply with scheduled follow-up and with management of toxicity
  • -Age 1 month-18 years
  • -Available venous access port
  • -Written informed consent from patients or from parents or legal guardians for minor patients, according to local law and regulations
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years)
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Patient refusal or parent refusal
  • -Patients with pre-existing liver disease
  • -Other serious illnesses or medical conditions

研究者

发起方
Erasmus MC

相似试验